The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacodynamic and pharmacokinetic characterization of tumor proliferation during acute sunitinib (SU) withdrawal.
B. H. Chao
No relevant relationships to disclose
M. R. Harrison
No relevant relationships to disclose
J. Kolesar
No relevant relationships to disclose
M. Vanderhoek
No relevant relationships to disclose
S. Perlman
No relevant relationships to disclose
J. C. Eickhoff
No relevant relationships to disclose
L. Carmichael
No relevant relationships to disclose
D. B. Alberti
No relevant relationships to disclose
G. Wilding
No relevant relationships to disclose
R. Jeraj
No relevant relationships to disclose
G. Liu
Research Funding - Pfizer